Endogenous glucocorticoids protect against TNF-alpha-induced increases in anxiety-like behavior in virally infected mice

Molecular Psychiatry

Volumn 12, Issue 4, 2007, Pages 408-417

  Silverman, M N ^a   Macdougall, M G ^b   Hu, F ^a   Pace, T W W ^a   Raison, C L ^a   Miller, A H ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Anxiety; Glucocorticoids; Open field behavior; TNF alpha; TNF R1 knockout mice; Viral infection

Indexed keywords

GLUCOCORTICOID; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADRENALECTOMY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; BRAIN REGION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; GENE EXPRESSION; KNOCKOUT MOUSE; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REARING; WILD TYPE;

ADRENALECTOMY; ANALYSIS OF VARIANCE; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BRAIN; EXPLORATORY BEHAVIOR; GLUCOCORTICOIDS; HERPESVIRIDAE INFECTIONS; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUROMEGALOVIRUS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RIBONUCLEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33947665608     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/sj.mp.4001921     Document Type: Article

References (66)

1. Silverman MN, Pearce BD, Biron CA, Miller AH. Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. Viral Immunol 2005; 18: 41-78.
2. Turnbull AV, Rivier CL. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 1999; 79: 1-71.
3. Silverman MN, Miller AH, Biron CA, Pearce BD. Characterization of an interleukin-6- and adrenocorticotropin-dependent, immune-to-adrenal pathway during viral infection. Endocrinology 2004; 145: 3580-3589.
4. Glezer I, Rivest S. Glucocorticoids: protectors of the brain during innate immune responses. Neuroscientist 2004; 10: 538-552.
5. Miller AH, Pearce BD, Ruzek MC, Biron CA. Interactions between the hypothalamic-pituitary-adrenal axis and immune system during viral infection: pathways for environmental effects on disease expression. In: McEwen BS (ed). Handbook of Physiology. Oxford University Press: New York, 2001, pp 425-450.
6. Schobitz B, Reul JM, Holsboer F. The role of the hypothalamic-pituitary- adrenocortical system during inflammatory conditions. Crit Rev Neurobiol 1994; 8: 263-291.
7. Webster JI, Sternberg EM. Role of the hypothalamic-pituitary-adrenal axis, glucocorticoids and glucocorticoid receptors in toxic sequelae of exposure to bacterial and viral products. J Endocrinol 2004; 181: 207-221.
8. Adcock IM, Caramori G. Cross-talk between pro-inflammatory transcription factors and glucocorticoids. Immunol Cell Biol 2001; 79: 376-384.
9. De Bosscher K, Vanden Berghe W, Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol 2000; 109: 16-22.
10. Kovalovsky D, Refojo D, Holsboer F, Arzt E. Molecular mechanisms and Th1/Th2 pathways in corticosteroid regulation of cytokine production. J Neuroimmunol 2000; 109: 23-29.
11. Webster JC, Cidlowski JA. Mechanisms of glucocorticoid-receptor-mediated repression of gene transcription. Trends Endocrinol Metab 1999; 10: 396-402.
12. Nadeau S, Rivest S. Glucocorticoids play a fundamental role in protecting the brain during innate immune response. J Neurosci 2003; 23: 5536-5544.
13. Kapcala LP, Chautard T, Eskay RL. The protective role of the hypothalamic-pituitary-adrenal axis against lethality produced by immune, infectious, and inflammatory stress. Ann NY Acad Sci 1995; 771: 419-437.
14. Price P, Olver SD, Silich M, Nador TZ, Yerkovich S, Wilson SG. Adrenalitis and the adrenocortical response of resistant and susceptible mice to acute murine cytomegalovirus infection. Eur J Clin Invest 1996; 26: 811-819.
15. Ruzek MC, Pearce BD, Miller AH, Biron CA. Endogenous glucocorticoids protect against cytokine-mediated lethality during viral infection. J Immunol 1999; 162: 3527-3533.
16. Ruzek MC, Miller AH, Opal SM, Pearce BD, Biron CA. Characterization of early cytokine responses and an interleukin (IL)-6-dependent pathway of endogenous glucocorticoid induction during murine cytomegalovirus infection. J Exp Med 1997; 185: 1185-1192.
17. Dantzer R. Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun 2001; 15: 7-24.
18. Maier SF, Watkins LR. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev 1998; 105: 83-107.
19. Dunn AJ, Swiergiel AH. The role of cytokines in infection-related behavior. Ann NYAcad Sci 1998; 840: 577-585.
20. Anisman H, Merali Z, Poulter MO, Hayley S. Cytokines as a precipitant of depressive illness: animal and human studies. Curr Pharm Des 2005; 11: 963-972.
21. Barak O, Goshen I, Ben-Hur T, Weidenfeld J, Taylor AN, Yirmiya R. Involvement of brain cytokines in the neurobehavioral disturbances induced by HIV-1 glycoprotein120. Brain Res 2002; 933: 98-108.
22. Bluthe RM, Laye S, Michaud B, Combe C, Dantzer R, Parnet P. Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide-induced sickness behaviour: a study with interleukin-1 type I receptor-deficient mice. Eur J Neurosci 2000; 12: 4447-4456.
23. Bluthe RM, Michaud B, Poli V, Dantzer R. Role of IL-6 in cytokine-induced sickness behavior: a study with IL-6 deficient mice. Physiol Behav 2000; 70: 367-373.
24. Kozak W, Poli V, Soszynski D, Conn CA, Leon LR, Kluger MJ. Sickness behavior in mice deficient in interleukin-6 during turpentine abscess and influenza pneumonitis. Am J Physiol 1997; 272: R621-R630.
25. Maier SF, Wiertelak EP, Martin D, Watkins LR. Interleukin-1 mediates the behavioral hyperalgesia produced by lithium chloride and endotoxin. Brain Res 1993; 623: 321-324.
26. Morrow JD, Opp MR. Diurnal variation of lipopolysaccharide-induced alterations in sleep and body temperature of interleukin-6-deficient mice. Brain Behav Immun 2005; 19: 40-51.
27. Pugh CR, Johnson JD, Martin D, Rudy JW, Maier SF, Watkins LR. Human immunodeficiency virus-1 coat protein gp120 impairs contextual fear conditioning: a potential role in AIDS related learning and memory impairments. Brain Res 2000; 861: 8-15.
28. Swiergiel AH, Smagin GN, Johnson LJ, Dunn AJ. The role of cytokines in the behavioral responses to endotoxin and influenza virus infection in mice: effects of acute and chronic administration of the interleukin-1-receptor antagonist (IL-1ra). Brain Res 1997; 776: 96-104.
29. Swiergiel AH, Dunn AJ. The roles of IL-1, IL-6, and TNFalpha in the feeding responses to endotoxin and influenza virus infection in mice. Brain Behav Immun 1999; 13: 252-265.
30. Yirmiya R, Weidenfeld J, Barak O, Avitsur R, Pollak Y, Gallily R et al. The role of brain cytokines in mediating the behavioral and neuroendocrine effects of intracerebral mycoplasma fermentans. Brain Res 1999; 829: 28-38.
31. Pollak Y, Ovadia H, Orion E, Yirmiya R. The EAE-associated behavioral syndrome: II. Modulation by anti-inflammatory treatments. J Neuroimmunol 2003; 137: 100-108.
32. Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 2003; 463: 3-33.
33. Belzung C, Griebel G. Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav Brain Res 2001; 125: 141-149.
34. Yirmiya R, Rosen H, Donchin O, Ovadia H. Behavioral effects of lipopolysaccharide in rats: involvement of endogenous opioids. Brain Res 1994; 648: 80-86.
35. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res 1996; 711: 163-174.
36. Yirmiya R, Barak O, Avitsur R, Gallily R, Weidenfeld J. Intracerebral administration of Mycoplasma fermentans produces sickness behavior: role of prostaglandins. Brain Res 1997; 749: 71-81.
37. Szechtman H, Sakic B, Denburg JA. Behaviour of MRL mice: an animal model of disturbed behaviour in systemic autoimmune disease. Lupus 1997; 6: 223-229.
38. Schobitz B, Pezeshki G, Pohl T, Hemmann U, Heinrich PC, Holsboer F et al. Soluble interleukin-6 (IL-6) receptor augments central effects of IL-6 in vivo. FASEB J 1995; 9: 659-664.
39. Bianchi M, Sacerdote P, Ricciardi-Castagnoli P, Mantegazza P, Panerai AE. Central effects of tumor necrosis factor alpha and interleukin-1 alpha on nociceptive thresholds and spontaneous locomotor activity. Neurosci Lett 1992; 148: 76-80.
40. Yirmiya R, Avitsur R, Donchin O, Cohen E. Interleukin-1 inhibits sexual behavior in female but not in male rats. Brain Behav Immun 1995; 9: 220-233.
41. Lacosta S, Merali Z, Anisman H. Influence of interleukin-1beta on exploratory behaviors, plasma ACTH, corticosterone, and central biogenic amines in mice. Psychopharmacology 1998; 137: 351-361.
42. Dunn AJ, Swiergiel AH. Effects of interleukin-1 and endotoxin in the forced swim and tail suspension tests in mice. Pharmacol Biochem Behav 2005; 81: 688-693.
43. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993; 73: 457-467.
44. Pezeshki G, Pohl T, Schobitz B. Corticosterone controls interleukin-1 beta expression and sickness behavior in the rat. J Neuroendocrinol 1996; 8: 129-135.
45. Barak O, Weidenfeld J, Goshen I, Ben-Hur T, Taylor AN, Yirmiya R. Intracerebral HIV-1 glycoprotein 120 produces sickness behavior and pituitary-adrenal activation in rats: role of prostaglandins. Brain Behav Immun 2002; 16: 720-735.
46. Schrott LM, Crnic LS. Increased anxiety behaviors in autoimmune mice. Behav Neurosci 1996; 110: 492-502.
47. Yamada K, Iida R, Miyamoto Y, Saito K, Sekikawa K, Seishima M et al. Neurobehavioral alterations in mice with a targeted deletion of the tumor necrosis factor-alpha gene: implications for emotional behavior. J Neuroimmunol 2000; 111: 131-138.
48. Fiore M, Probert L, Kollias G, Akassoglou K, Alleva E, Aloe L. Neurobehavioral alterations in developing transgenic mice expressing TNF-alpha in the brain. Brain Behav Immun 1996; 10: 126-138.
49. Fiore M, Alleva E, Probert L, Kollias G, Angelucci F, Aloe L. Exploratory and displacement behavior in transgenic mice expressing high levels of brain TNF-alpha. Physiol Behav 1998; 63: 571-576.
50. Connor TJ, Song C, Leonard BE, Merali Z, Anisman H. An assessment of the effects of central interleukin-1beta, -2, -6, and tumor necrosis factor-alpha administration on some behavioural, neurochemical, endocrine and immune parameters in the rat. Neuroscience 1998; 84: 923-933.
51. Pan W, Kastin AJ, Rigai T, McLay R, Pick CG. Increased hippocampal uptake of tumor necrosis factor alpha and behavioral changes in mice. Exp Brain Res 2003; 149: 195-199.
52. Maes M, Song C, Lin A, De Jongh R, Van Gastel A, Kenis G et al. The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine 1998; 10: 313-318.
53. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001; 58: 445-452.
54. Lokensgard JR, Chao CC, Gekker G, Hu S, Peterson PK. Benzodiazepines, glia, and HIV-1 neuropathogenesis. Mol Neurobiol 1998; 18: 23-33.
55. Taupin V, Jayais P, Descamps-Latscha B, Cazalaa JB, Barrier G, Bach JF et al. Benzodiazepine anesthesia in humans modulates the interleukin-1 beta, tumor necrosis factor-alpha and interleukin-6 responses of blood monocytes. J Neuroimmunol 1991; 35: 13-19.
56. Zavala F, Taupin V, Descamps-Latscha B. In vivo treatment with benzodiazepines inhibits murine phagocyte oxidative metabolism and production of interleukin 1, tumor necrosis factor and interleukin-6. J Pharmacol Exp Ther 1990; 255: 442-450.
57. Watanobe H, Takebe K. Intravenous administration of tumor necrosis factor-alpha stimulates corticotropin releasing hormone secretion in the push-pull cannulated median eminence of freely moving rats. Neuropeptides 1992; 22: 81-84.
58. Bernardini R, Kamilaris TC, Calogero AE, Johnson EO, Gomez MT, Gold PW et al. Interactions between tumor necrosis factor-alpha, hypothalamic corticotropin-releasing hormone, and adrenocorticotropin secretion in the rat. Endocrinology 1990; 126: 2876-2881.
59. Butterweck V, Prinz S, Schwaninger M. The role of interleukin-6 in stress-induced hyperthermia and emotional behaviour in mice. Behav Brain Res 2003; 144: 49-56.
60. Lenczowski MJ, Bluthe RM, Roth J, Rees GS, Rushforth DA, van Dam AM et al. Central administration of rat IL-6 induces HPA activation and fever but not sickness behavior in rats. Am J Physiol 1999; 276: R652-R658.
61. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 2003; 160: 1554-1565.
62. Maes M, Lin AH, Delmeire L, Van Gastel A, Kenis G, De Jongh R et al. Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. Biol Psychiatry 1999; 45: 833-839.
63. Sluzewska A, Rybakowski J, Bosmans E, Sobieska M, Berghmans R, Maes M et al. Indicators of immune activation in major depression. Psychiatry Res 1996; 64: 161-167.
64. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000; 22: 370-379.
65. Cannon JG, Angel JB, Ball RW, Abad LW, Fagioli L, Komaroff AL. Acute phase responses and cytokine secretion in chronic fatigue syndrome. J Clin Immunol 1999; 19: 414-421.
66. Demitrack MA, Crofford LJ. Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. Ann NY Acad Sci 1998; 840: 684-697.